Navigation Links
Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients
Date:3/23/2009

with offices in Bethesda, MD and Munich, Germany. The Company is focused on developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. The Company's novel antibody technology is based on its proprietary BiTE(R) antibody platform, representing a new class of antibodies that specifically activate T cells from the patient's own immune system to eliminate cancer cells or other disease related cells. Four of the Company's antibodies are currently in clinical trials, with the remainder of its product pipeline in preclinical development. The Company's lead program is a BiTE antibody known as blinatumomab, or MT103. It is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. Micromet's second BiTE antibody in clinical development is MT110, which targets the epithelial cell adhesion molecule (EpCAM). The Company owns all rights to MT110, which is currently in a phase 1 clinical trial for the treatment of patients with solid tumors. The Company's third clinical stage antibody is adecatumumab, also known as MT201, a traditional human monoclonal antibody that targets EpCAM-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. Micromet licensed a fourth clinical stage antibody, MT293, to TRACON Pharmaceuticals, Inc. MT293 is being developed in a phase 1 clinical trial for the treatment of patients with cancer. The Company's preclinical programs include MT203 being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as
'/>"/>
SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Micromet Key Events for 2009
2. Micromet Expands Committed Equity Financing Facility to $75 Million
3. Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells
4. Micromet Presents Data at ESMO 2008 on Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy
5. Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE
6. Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results
7. Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
8. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
9. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
10. Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
11. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)...  Bio-Techne Corporation (NASDAQ: TECH ) announced today ... the new Simple Plex platform through its Proteins Platform ... re-branding of the previously acquired CyPlex instrument platform from ... transformative immunoassay technology which integrates an innovatively designed microfluidic ...
(Date:1/22/2015)... DUBLIN , Jan. 22, 2015 Research and Markets ... of the "Infectious Disease Diagnostics Market by Product, ... report to their offering. , The ... CAGR of 7.9% to reach $18,156.2 million by 2019 ...
(Date:1/22/2015)... The Parenteral Drug Association (PDA) today announced the launch ... Pharmaceutical Manufacturing,s Future. The Manufacturing Science ... , Highlight the ongoing focus PDA has on pharmaceutical and ... filling known gaps in current manufacturing science as well as ...
Breaking Medicine Technology:Bio-Techne Launches Simple Plex Platform 2Bio-Techne Launches Simple Plex Platform 3Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 2Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 3PDA Launches Manufacturing Science Program(SM) 2PDA Launches Manufacturing Science Program(SM) 3
... MedImmune today announced,that it has initiated a Phase ... healthy children one month to 12 months of age ... is,the most common respiratory infection in infants and can ... is a serious respiratory disease that can have significant ...
... Meeting -, - Conference call to be hosted ... BRANFORD, Conn., Nov. 3 CuraGen Corporation,(Nasdaq: CRGN ... II,trial of CR011-vcMMAE, an antibody-drug conjugate that targets GPNMB, ... Stage IV melanoma.,Dr. Patrick Hwu, Co-Principal Investigator, and Professor ...
Cached Medicine Technology:MedImmune Advances Pediatric Disease Prevention Program With Start of Phase 1/2a Clinical Trial for Respiratory Syncytial Virus Vaccine 2CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 2CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 3CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 4CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 5CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 6CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 7
(Date:1/22/2015)... AZ (PRWEB) January 22, 2015 Padre Murphy's ... long supporter of Pro Player Health Alliance (PPHA). ... Padre Murphy's in getting everyone, including NFL greats, treated for ... of the leading groups supporting the cause in the valley. ...
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, has recently ... View website of AngelWeddingDress.com to find more details. ... online for a bridal party. AngelWeddingDress offers a variety ... Its maternity wedding dresses are specially designed for 2015. ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post explaining the main ... , Auto insurance quotes help many drivers find the ... to call an agent or visit an agency for price ... website: http://autocarinsurancebest.com/ . , Every business who relies heavily ...
(Date:1/22/2015)... Calif. (PRWEB) January 22, 2015 ... Susan Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were ... their leadership in advancing biotechnology, biomedical science, medical ... and Olsen each received the “2014 Life Sciences ...
(Date:1/22/2015)... EBSCO Information Services (EBSCO) and the ... in an effort to further promote visibility and adoption of ... long made AMA journals available via its subscription services, EBSCO ... Network. , Long known as both a subscription ...
Breaking Medicine News(10 mins):Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4
... , August is National ... Pa., Aug. 3 Department of Health Secretary Everette James ... Immunization Awareness Month. , , "Recommended vaccinations ... you and your family are up-to-date on these immunizations is ...
... to settle debate over their usefulness , MONDAY, Aug. 3 ... wearing surgical face masks to ward off the flu, and ... up the confusion. , Researchers in Hong Kong found that ... can help keep transmission rates for the seasonal flu down, ...
... , , , BEDFORD, Mass., Aug. ... leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products ... quarter ended June 27, 2009. , , Highlights of the ... Revenues of $403.1 million. , Third quarter 2009 ...
... Results , , , ... announced today financial results for the three months ended June 30, 2009. ... 2009, compared to $6.3 million for the same period in 2008. ... million, compared to a net loss of $8.6 million for the same ...
... , , WASHINGTON, Aug. 3 ... top Catholic charitable organizations to condemn the Obama healthcare plan in ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081105/DC44231LOGO ) , ... de Paul and the Catholic Health Association are urging their members ...
... finds increases in use of other psychotropic medications , ... U.S. residents almost doubled between 1996 and 2005, along ... psychotropic medications, a new report shows. , The increase ... 10 percent of people over the age of 6 ...
Cached Medicine News:Health News:Corrected: Secretary of Health Urges Pennsylvanians to Get Immunized 2Health News:Corrected: Secretary of Health Urges Pennsylvanians to Get Immunized 3Health News:Surgical Masks Help Ward Off Flu, Maybe 2Health News:Surgical Masks Help Ward Off Flu, Maybe 3Health News:Surgical Masks Help Ward Off Flu, Maybe 4Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 2Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 3Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 4Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 5Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 6Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 7Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 8Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 9Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 10Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 11Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 12Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 13Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 14Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 15Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 16Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 17Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 18Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 19Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 20Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 21Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 22Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 23Health News:DURECT Corporation Announces Second Quarter 2009 Financial 2Health News:DURECT Corporation Announces Second Quarter 2009 Financial 3Health News:DURECT Corporation Announces Second Quarter 2009 Financial 4Health News:DURECT Corporation Announces Second Quarter 2009 Financial 5Health News:DURECT Corporation Announces Second Quarter 2009 Financial 6Health News:DURECT Corporation Announces Second Quarter 2009 Financial 7Health News:DURECT Corporation Announces Second Quarter 2009 Financial 8Health News:DURECT Corporation Announces Second Quarter 2009 Financial 9
... images are transmitted through sorted ... picture and transmit it to ... flexoscopes are designed for rough, ... repaired at low cost if ...
Bipolar gingivoplasty loop. Individual sterile packs....
Electric high speed system....
The XK-PRO 100 High Speed Drill System is a compact, lightweight design that offers new technological and performance standards for a combination of surgical procedures....
Medicine Products: